A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant

Appl Radiat Isot. 2016 Oct:116:13-21. doi: 10.1016/j.apradiso.2016.07.016. Epub 2016 Jul 20.

Abstract

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT.

Keywords: (131)I-rituximab; Iodine-131; Non-Hodgkin's lymphoma; Radioimmunotherapy; Rituximab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Isotope Labeling
  • Lymphoma, Non-Hodgkin / pathology*
  • Lymphoma, Non-Hodgkin / therapy*
  • Malaysia
  • Middle Aged
  • Pilot Projects
  • Radioimmunotherapy / methods
  • Radiopharmaceuticals
  • Radiotherapy Dosage
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Radiopharmaceuticals
  • Rituximab
  • 131I-rituximab